Company intelligence / Profile preview

Farma de Colombia

Bogota, Bogota D.C., Colombiafarmadecolombia.com ↗

Ownership: Private
Employees: ~151
Development stage: Commercial

Overview

Farma de Colombia has over 60 years of experience providing high-quality pharmaceutical products to the Colombian market and neighboring countries. It is recognized for innovative branded generics as well as licensed multinational products. In 2019 it entered an exclusive license with Henlius to commercialize HLX01 (rituximab biosimilar) for non-Hodgkin lymphoma in several Latin American countries[1][3][6].

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Henlius

Beyond the preview

Go deeper on Farma de Colombia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farma de Colombia.

Explore the full profile